New Search

If you are not happy with the results below please do another search

2034 search results for:

61

Merck to pay Daiichi Sankyo up to $22bn to collaborate on 3 new cancer drugs

In a deal potentially worth up to US$22 billion, Merck (known as MSD outside of the United States and Canada) has entered into a collaboration agreement with Japan-based Daiichi Sankyo to co-develop and co-commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd).

67

Sphere Fluidics expands Cyto-Mine capabilities to meet cGMP requirements for drug manufacture workflows

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, has updated its flagship platform, Cyto-Mine, enabling it to be compliant with current Good Manufacturing Practice (cGMP) regulations enforced by the US FDA. By meeting these requirements, the company now provides a solution to increase efficiency and productivity of cell […]

68

CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for micro-physiological systems

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), and LifeNet Health LifeSciences, a non-profit, global leader in human research solutions, will collaborate to supply validated primary human cells for use with CN Bio’s PhysioMimix OOC range of MPS. Under the agreement, LifeNet Health’s high-quality, MPS validated, hepatic […]

69

ISSCR introduces checklist to promote global best practices for human stem cell research

ISSCR introduces checklist to promote global best practices for human stem cell research Recommendations from the Standards for Human Stem Cell Use in Research [1],  published in June by the International Society for Stem Cell Research (ISSCR), include a publishing “checklist” that is now being used by laboratory scientists and implemented in the review process […]

70

Broken String Biosciences Closes $15M Series A Funding Round

Broken String Biosciences, a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, has closed a US$15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from HERAN Partners, and existing investors Tencent and Dieter von Holtzbrinck Ventures […]